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for cancer
Mael Chalret du Rieu1, Thomas Filleron2, Benoit Beluchon1, Marine Humeau1, Charles-Henri Julio1, Eric Bloom1,
Laurent Ghouti1, Sylvain Kirzin1, Guillaume Portier1, Bernard Pradère1 and Nicolas Carrère1*Abstract
Objective: The aim of this study was to analyze the profile of tumor recurrence for patients operated on for cancer
of oesophagogastric junction or oesophagus by Ivor-Lewis oesophagectomy.
Methods: Patients undergoing potentially curative Ivor-Lewis oesophageal resection between January 1999 to
December 2008 at a single center institution were retrospectively analyzed. Their clinical records, details of surgical
procedure, postoperative course, pathological findings, recurrence and long term survival were reviewed retrospectively.
Univariate and multivariate survival analyses were performed.
Results: One hundred and twenty patients were analyzed. Fifty three patients (44%) presented recurrence during
median follow-up of 58 months. Five-year relapse free survival (RFS) rate was 51% (95%CI = [46; 65%]). On multivariate
analysis, pT stage > 2 (HR = 2.42, 95%CI = [1.22; 4.79] p = 0.011), positive lymph node status (HR = 3.69; 95% CI = [1.53;
8.96] p = 0.004) and lymph node ratio > 0.2 (HR = 2.57; 95%CI = [1.38; 4.76] p = 0.003) were associated with a poorer RFS
and their combination was correlated to relapse risk. Moreover, preoperative tumor stenosis was associated with an
increased risk of local recurrence (HR = 3.46; 95% CI = [1.38; 8.70] p = 0.008) whereas poor or undifferentiated tumor was
associated with an increased risk of distant recurrence (HR = 3.32; 95% CI = [1.03; 10.04] p = 0.044).
Conclusion: pT stage > 2, positive lymph node status and lymph node ratio > 0.2 are independent prognostic factors of
recurrence after Ivor-Lewis surgery for cancer. Their combination is correlated with an increasing risk of recurrence that
may argue favorably, in addition with preoperative tumor stenosis assessment, for adjuvant treatment or reinforced
follow-up.
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Oesophageal cancer is a major public health concern as it
is the fourth cause of cancer death after lung, colorectal
and prostate cancers. Without contraindication of resec-
tability or operability, surgery is the standard treatment of
curative intent. However, in spite of optimal R0 resection,
overall 5-year survival is poor, about 20 to 30%, because of
frequent tumor recurrence [1]. Thus, exclusive chemora-
diotherapy has become an alternative to surgical treat-
ment, with a comparable overall survival in locally
advanced squamous cell carcinoma [2,3]. However, ratio
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reproduction in any medium, provided the orincidence is changing with an increasing incidence of
adenocarcinoma developed on Barrett oesophagus in
Western countries [4]. Regarding adenocarcinoma, com-
bination of neo-adjuvant treatment seems to provide im-
proved survival despite of its own morbi-mortality [5].
Study of tumor relapse could therefore allow adaptation
and targeting perioperative treatment to patients with high
risk of recurrence. The aim of this study was to analyze
the profile of tumor recurrence in a homogenous group of
patients operated on for cancer of oesophagogastric junc-
tion or oesophagus by Ivor-Lewis oesophagectomy.Methods
From January 1999 to December 2008, 120 consecutive
patients underwent an Ivor-Lewis oesophagectomy for
cancer at a single institution. Their clinical records werel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(BMI), nutritional factors, American Society of Anesthes-
iologists (ASA) score, symptoms at diagnosis, preoperative
treatment, details of the surgical procedure, pathological
findings, postoperative course, recurrence and long term sur-
vival. The research was carried out in compliance with the
Helsinki Declaration and approved by the Comité de Protec-
tion des Personnes (CPP) Sud Ouest (Toulouse, France).
Preoperative evaluation
Operability and resectability criteria were those usually
used in oncologic guidelines [6]. All surgical indications
were validated in pluridisciplinary meeting. Endoscopy,
computed tomography and barium swallows were sys-
tematically performed. Ultrasonographic endoscopy (EUS)
was performed systematically as soon as it was technically
available and when there was no non-traversable stric-
tures. Positron emission tomography (PET) was done
depending on the suspicion of metastatic extension. Fea-
tures of lymph nodes on EUS and computed tomography,
including size 1 cm or more, rounded shape, well demar-
cated borders, and heterogeneous patterns, were used to
describe the nodes as benign or malignant.
Preoperative tumor stenosis was defined as a difficulty
or inability for the fiberscope (11.6 mm standard dia-
meter) to pass through the lesion and/or at least a hemi-
circumferential narrowing light on barium swallow (both
sides of the oesophagus narrowed by tumor noticed on
at least one radiologic incidence).
Neo-adjuvant chemotherapy (CT) (Platin and 5 Fluo-
rouracil) or chemoradiotherapy (CRT) (45 to 50 Gy and
concomitant Platin/5 fluorouracil chemotherapy) was
delivered in case of locally advanced cancer (T stage ≥ 3
and/or N stage ≥ 1). CRT was preferred for high volume
tumors and/or for limited resection margins.
Clinical response was defined by regression of dysphagia
and tumor size on post induction computed tomography.
Endoscopic control, EUS nor PET were not routinely
performed.
Immunonutrition was systematically delivered for seven
preoperative days.
Surgical procedure
Conventional orotracheal intubation was performed
without selective bronchial intubation. Gastrolysis was
done through laparoscopy or midline laparotomy. Tho-
racotomy was done through a right posterolateral thora-
cotomy in the fifth intercostal space. Gastric transplant
was created in the chest and anastomosed mechanically
to the oesophagus. An extended upper abdominal lym-
phadenectomy was routinely performed comprising en-
bloc resection of the nodal tissue along the common
hepatic and proximal splenic arteries together with that
at the origins of the left gastric artery and celiac axis.The lesser omentum was divided, encompassing the
nodes along the lesser curve and an en-bloc hiatal dis-
section was performed removing the left and right para-
cardial stations and the respective crura. Within the
thorax, standard lymphadenectomy was routinely per-
formed that comprised middle and lower paraoesopha-
geal nodes, paratracheal, carinal, left and right bronchial
nodes and left recurrent laryngeal nerve chain. No cer-
vical lymphadenectomy or three-field lymphadenectomy
was undertaken even for tumors of middle third
oesophagus. Patients were extubated in recovery room
and then transferred to the ward.
Postoperative data
All tumors were staged post surgically by the TNM clas-
sification system of the American Joint Committee on
Cancer 2002 for oesophageal or gastric cancer depend-
ing on tumor localization. The resection was designated
R0 when it was thought that both macroscopic and
microscopic clearance had been achieved; R1 when it
was microscopically incomplete (margin inferior to one
millimeter), and there was histologic evidence of inva-
sion of the longitudinal or lateral margins; and R2 when
it was macroscopically incomplete, with macroscopic
residual tumor after surgery. Median lymph node ratio
was defined by the ratio between number of positive
lymph nodes and number of resected lymph nodes.
Operative mortality and morbidity was defined as any
death or complication during the first 30 days after op-
eration. A major complication was defined as any com-
plication > 3 on Clavien Dindo classification.
Follow up data were obtained from patient charts,
tumor registry and referring physicians. A clinical exa-
mination was carried out every three to six months for
three years. Thoraco-abdominal computed tomography
was performed at least twice a year for 3 years or ac-
cording to symptoms. Endoscopy was done in case of
dysphagia.
For recurrence study, final date of follow-up was
scheduled for March 31, 2010. Histologic, cytologic, or
unequivocal radiologic proof was required before re-
currence was diagnosed. Recurrence was classified into
three categories: local recurrence (occurring at the sur-
gical resection site or on cervical site), distant recur-
rence (in case of distant metastasis) and disseminated
(in case of local and distant recurrence). Operative
deaths and deaths that were not related to cancer were
included in the survival statistics.
Statistical analysis
Data were summarized by frequency and percentage for
categorical variables and by median and range for con-
tinuous variables. All survival times were calculated
from the date of surgery. Relapse free survival (RFS) and
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Meier methods using the following first-event defini-
tions: loco-regional or distant recurrence for relapse
free survival and death from any cause for overall sur-
vival. Univariate analysis was performed using the Log-
Rank test. The following three step algorithm using Cox
proportional hazard modeling was performed:
Step 1: Influence of pre-operative variables with a
p-value <0.05 in univariate analysis was evaluated.
Step 2: Influence of pathological variables with a
p-value <0.05 in univariate analysis was evaluated.
Step 3: Influence of pre-operative and pathological
variables statistically significative in step 1 and 2
was evaluated.
Competing risks multivariate analysis was conducted
using the Fine & Gray model in order to evaluate the
influence of different variables on the cumulative inci-
dence in the presence of competing risks (i.e local recur-
rence vs distant relapse).
All p-values reported were two-sided. For all statistical
tests, differences were considered significant at the 5%
level. Statistical analyses were performed using the
STATA 10.0 software.Results
Preoperative results
One hundred and twenty patients were included. Me-
dian age at surgery was 62 years [27-79 years] (Table 1).
Sex ratio male: female was 4: 1. Dysphagia was the main
symptom (68%) and 16% of patients were asymptomatic
among them 11.6% were diagnosed for Barrett oesopha-
gus follow-up and 5% (n = 6) on an examination pres-
cribed for other indication. Severe weight loss (weight
loss exceeding 10% of usual weight in one month or 15%
in six months) was present in 20% of patients as 32%
were overweight (BMI > 25 Kg/m2) and 6% were obese
(BMI > 30 Kg/m2). Median BMI was 23.5 Kg/m2 [12.5-
43.3 Kg/m2]. Most lesions were localized on the lower
third of oesophagus (49%). EUS was performed on 62
patients and lymph node invasion was suspected in 62%
of cases (n = 38). PET was performed in 20 patients
(16%).
Neo-adjuvant CT was administered to 25 patients (21%)
and CRT to 12 patients (10%). Clinical response was ob-
tained in 76% of cases (n = 28).Operative results
Median length of procedures was 340 minutes [185-525 -
minutes]. Fifteen percent of patient required blood trans-
fusion. Median length of oro-tracheal intubation was
8.3 hours [5.70-14.3 hours].Postoperative results
Median length of stay was 17 days [8-109 days]. Post-
operative mortality was 3% with 15% of major compli-
cation (> 3 Clavien Dindo classification) (Table 1). Main
complications were respiratory complications (15%).
Anastomotic fistula rate was 6.6% (n = 8).
Pathological findings
Adenocarcinoma was found in 62% of cases and squa-
mous cell carcinoma in 38%. Complete resection was
obtained in 79% of patients. Most R1 resections were be-
cause of positive circumferential resection margin (17%).
Inferior longitudinal margin was positive in one patient
(0.8%) and superior longitudinal margin in two patients
(1.7%). On histopathological assessment of the resected
specimens, the pT stage was: pT0 (5%), pTis (5%), pT1
(24%), pT2 (18%), pT3 (46%) and pT4 (3%). Most lesions
were moderately or well differentiated (68%). Lymph
node involvement was present in 49% of cases with
median number of resected lymph node of 15 [4-43].
Median lymph node ratio was 0.14 [0-0.9].
Overall survival
Four patients were lost of follow-up after a median
follow-up of 47 months [28-67 months] and were kept
in the study. After a median follow-up of 58 months
[48.4-69.1 months], 57 patients have died. The 1- and
5-year overall survival probabilities were 86.9% (95%
CI = [79.5; 91.7]) and 49.0% (95%CI = [38.3; 58.8]).
Relapse free survival
Fifty three patients (44%) presented recurrence during
follow-up with a median delay of 10.3 months [2.4-47.5
months] without any difference according to the type of
recurrence. The 1- and 5-years relapse free survival rates
were respectively 73% (95% CI = [64; 80%]) and 51% (95%
CI = [46; 65%]) (Figure 1). Local recurrence was the most
frequent first event type (n = 30, 56%). Among them, 10
patients presented cervical recurrence. Distant and dis-
seminated recurrence occurred respectively in 17 patients
(32%) and 6 patients (11%). Most recurrences occurred
during the first year (58%) and none after the fourth year
of follow-up. Median survival in case of recurrence was
6.7 months [1-36 months] for local recurrence and
9.8 months [2.1: 44] for distant recurrence.
Based on univariate analysis, several risk factors for
recurrence were identified (Table 2). Thus, age above
60 years (p = 0.04), loss of weight greater than 10% (p =
0.038), preoperative tumor stenosis (p < 0.0001), EUS posi-
tive lymph node (p = 0.023), oesophagogastric junction
location of tumor (p = 0.005), poor tumor differentiation
(p = 0.031), pT stage > 2 (p < 0.0001), positive lymph
node status (p < 0.0001), incomplete resection (p =
0.002), positive circumferential margin (p = 0.0019),
Table 1 Perioperative data
n % n %
Total 120 100 Total 120 100
Preoperative data Histopathological findings
Age (years) Histology
- ≤ 60 46 38 - Adenocarcinoma 75 62
- > 60 74 62 - Squamous cell carcinoma 45 38
Sex pT stage
- Male 97 81 - 0 6 5
- Female 23 19 - is 6 5
Weight loss - 1 29 24
- ≤ 10% 96 80 - 2 21 18
- > 10% 24 20 - 3 55 46
Body Mass Index (Kg/m2) - 4 3 3
- ≥ 25 74 62 pN stage
- < 25 46 38 - 0 61 51
ASA Score - 1, 2 or 3 59 49
- 1 51 43 Number of positive lymph nodes
- 2 39 33 - 0 61 51
- 3 30 25 - 1-4 34 28
Risk factor - > 4 25 21
- Gastro-oesophageal Reflux Disease 44 37 Lymph node ratio
- Alcohol 71 59 - ≤ 0.2 88 73
- Tobacco 32 27 - > 0.2 32 27
Localisation pM stage
- Oesophagogastric junction 32 27 - 0 117 98
- Lower third oesophagus 59 49 - 1 3 3
- Mid third oesophagus 29 24 Differentiation
Tumor stenosis - undiff./poorly 23 21
- None 51 43 - moderately/well 88 79
- Incomplete 53 44 Resection
- Complete 16 13 - R0 95 79
TDM lymph node - R1 24 20
- No pathol. lymph node 93 77 - R2 1 1
- Pathol. lymph node 27 23 Circumferential margin
EUS results - Complete 99 83
usT 60 - Incomplete 21 17
- 1 & 2 33 55 Node capsular penetration
- 3 & 4 27 45 - No 115 96
usN 60 - Yes 5 4
- 0 23 38 Angiolymphatic invasion
- 1 38 62 - No 58 60
Preoperative treatment - Yes 39 40
- None 83 69 Neural invasion
- Chemotherapy 25 21 - No 54 57
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Table 1 Perioperative data (Continued)
- Chemo radiotherapy 12 10 - Yes 40 43
Postoperative data
30-day morbidity 53 44
- major 18 15
- minor 35 29
30-day mortality 4 3
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invasion (p < 0.0001), neural invasion (p < 0.0001), high
number of positive lymph nodes (p < 0.0001) and lymph
node ratio > 0.2 (p < 0.0001) were significantly asso-
ciated with a poorer RFS.
Results of multivariate analysis are summarized on
Table 3. In the multivariate analysis for pre-operative
variables (Step 1), only presence of tumor stenosis was
associated with an increased risk of relapse (HR = 3.36;
95% CI = [1.68; 6.72] p = 0.001).
For pathological data (Step 2), the following variables
were associated with a higher probability of relapse
in multivariate analysis: pT stage > 2 (HR = 2.91; 95%
CI = [1.16; 7.31] p = 0.023), positive lymph node status
(HR = 4.67; 95% CI = [1.47; 14.77] p = 0.009) and lymph
node ratio > 0.2 (HR = 2.71; 95% CI = [1.34; 5.51] p = 0.006).
When combining pre-operative and pathological vari-
ables statistically significative in the two previous multi-
variate analysis (Step 3), the following variables were
associated with an increased risk of relapse: pT stage > 2
(HR = 2.42; 95% CI = [1.22; 4.79] p = 0.011), positive lymph
node status (HR = 3.69; 95% CI = [1.53; 8.96] p = 0.004)
and lymph node ratio > 0.2 (HR = 2.57; 95% CI = [1.38;Figure 1 Kaplan-Meier Relapse Free Survival curve.4.76] p = 0.003). Relapse free survivals according to the
number of risk factors were presented on Figure 2 (p <
0.0001). Addition of risks factors was correlated with a
poorer RFS.
Competing risks analysis
In multivariate analysis (Table 3), only the presence of
preoperative tumor stenosis was associated with an
increased risk of local recurrence (HR = 3.46; 95% CI =
[1.38; 8.70] p = 0.008). There was a trend for presence of
positive lymph node (HR = 6.01; 95% CI = [0.84; 43.10]
p = 0.074) that did not reach statistical significance. Con-
cerning distant recurrence (Table 3), only the presence
of poor or undifferentiated tumor was associated with a
higher probability of distant recurrence (HR = 3.32; 95%
CI = [1.03; 10.04] p = 0.044).
Discussion
Several studies have identified different risk factors of
tumor recurrence after surgery of oesophageal cancer.
Positive lymph node status is the most frequent factor
identified [7-9]. It is also highlighted as an independent
risk factor in our study. However, the impact of lymph
Table 2 Relapse free survival - univariate analysis
Preoperative data % 5-y RFS (n) (n total = 120) p
Age (years) : <60 / >60 58.6 (16) / 45.6 (37) 0.0396
ASA score : 1-2 / 3 50.0 (41) / 55.1 (12) 0.6742
Sex : Male / Female 48.5 (46) / 61.8 (7) 0.1641
Histology : Adenocarcinoma / Squamous cell carcinoma 53.9 (34) / 43.0 (19) 0.7995
Weight loss (%) : ≤ 10 / > 10 56.3 (38) / 29.2 (15) 0.0379
Body Mass Index (Kg/m2) : ≤ 25 / > 25 51.2 (32) / 49.4 (21) 0.597
Gastro-oesophageal reflux disease : No / Yes 45.5 (36) / 60.4 (17) 0.2185
Tumor stenosis : No / Yes 77.9 (11) / 31.8 (42) <0.0001
TDM pathological lymph node : No / Yes 56.0 (37) / 33.7 (16) 0.063
EUS results
usT : 1&2 / 3&4 72.5 (9) / 52.0 (11) 0.1727
usN : 0 / 1 78.1 (4) / 51.7 (16) 0.0227
Preoperative treatment : No / CT or CRT 51.9 (37) / 49.2 (16) 0.7166
Tumor localization : Oesophagogastric jct. / Lower or mid third 40.2 (18) / 58.9 (35) 0.0046
Postoperative data % 5-y RFS (n) p
Differentiation: Undiff. or poorly diff. / Moderately or well diff. 40.9 (13) / 55.6 (35) 0.0313
pT Stage : T ≤ 2 / T > 2 75.9 (13) / 24.9 (40) <0.0001
pN Stage : N0 / N+ 82.9 (9) / 16.7 (44) <0.0001
Resection : R0 / R1 or R2 57.2 (37) / 25.0 (16) 0.002
Circumferential margin : Complete / Incomplete 56.9 (39) / 19.6 (14) 0.0019
Node capsular penetration : No/Yes 52.4 (49) / 20.0 (4) 0.0206
Angiolymphatic invasion : No / Yes 66.4 (17) / 19.4 (29) <0.0001
Neural invasion : No / Yes 66.5 (16) / 25.5 (28) <0.0001
Number of positive lymph nodes : 0 / 1-4 / >4 82.9 (9) / 23.4 (23) / 7.8 (21) <0.0001
Lymph node ratio : ≤ 0.2 / > 0.2 66.5 (26) / 0.0 (27) <0.0001
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nostic role of lymph node ratio ie ratio between positive
lymph nodes and resected lymph nodes. Ratios varying
from 0.1 to 0.5 have already been discussed [8,10]. In
this study, ratio was set at 0.2, low enough to be discri-
minating. It turns out to be an independent major risk
factor for relapse free survival that can be illustrated by
a 5-year RFS of 67% with a ratio ≤ 0.2 versus 0% with a
ratio > 0.2. An interesting finding of our study is the
independency of lymph node ratio as a risk factor, par-
ticularly independent from lymph node positivity what
could have been a confusing factor.
Other authors have also identified the number of in-
volved nodes as a prognostic factor [9,11]. These studies
show the importance of node involvement as a quantita-
tive and not only qualitative factor and are behind the
recent changes to the 2009 UICC TNM classification.
This last distinguishes nowadays different stages of nodal
involvement for oesophageal cancer, superimposed on the
oesophagogastric junction cancer classification, whereas itincluded only a single stage of nodal involvement in the
previous version [12].
Unfortunately, information on the presence of this
major prognostic factor is only obtained retrospectively
on specimen examination. It does not allow optimal
adaptation of neo-adjuvant treatment. Current diagnos-
tic methods combining computed tomography, EUS and
endoscopy permit an appropriate staging in 56% of cases
and adjunction of PET does not provide better sensiti-
vity for the preoperative lymph node diagnosis compared
to EUS or computed tomography (sensitivity of 0.57 vs
0.8 and 0.5 resp.) [13,14].
Indication of adjuvant treatment after oesophageal sur-
gery is not recommended even in case of lymph node
involvement but may be discussed if the patient is healthy,
demanding, and informed. However, lymph node invasion
seems to be a very accurate predictor of relapse free sur-
vival and may be used to identify patients requiring adju-
vant chemotherapy or chemoradiotherapy to treat systemic
metastases developing after primary resection [15].
Table 3 Relapse Free Survival - Multivariate analysis
Cox Model Competing risks & Fine & Gray Cox RFS
Relapse Free Survival Local recurrence Distant recurrence Step 3 : Final analysis
HR 95% CI p HR 95% CI p HR 95% CI p HR 95% CI p
Step 1 : Preoperative data
Weight loss (%)
- ≤ 10 1 1 1
- > 10 1.17 0.63; 2.19 0.615 0.81 0.34; 1.94 0.648 1.74 0.72; 4.22 0.218
Age (years)
- < 60 1 1 1
- > 60 1.79 0.99; 3.23 0.051 1.13 0.55; 2.32 0.731 2.4 0.91; 6.34 0.076
Tumor stenosis
- No 1 1 1 1
- Yes 3.36 1.68; 6.72 0.001 3.46 1.38; 8.70 0.008 2.21 0.78; 6.23 0.135 1.12 0.54; 2.39 0.757
Step 2 : Pathological findings
Tumor localization
- Oesophagogastric jct 1.16 0.55; 2.45 0.689 1.27 0.51; 3.16 0.61 0.92 0.30; 2.78 0.879
- Lower/mid third 1 1 1
Differentiation
- undiff./poorly 1.03 0.47; 2.28 0.933 0.32 0.07; 1.33 0.116 3.22 1.03; 10.04 0.044
- moderately/well 1 1 1
T Stage
- pT ≤ 2 1 1 1 1
- pT > 2 2.91 1.16; 7.31 0.023 1.03 0.28; 3.82 0.955 5.86 0.93; 37.15 0.06 2.42 1.22; 4.79 0.011
N Stage
- pN0 1 1 1 1
- pN+ 4.67 1.47; 14.77 0.009 6.01 0.84; 43.10 0.074 3.48 0.68; 17.81 0.135 3.69 1.53; 8.96 0.004
Resection
- R0 1 1 1
- R1 or R2 0.52 0.24; 1.13 0.098 0.99 0.35; 2.74 0.98 0.4 0.11; 1.48 0.174
Lymph node ratio
- ≤ 0.2 1 1 1 1
- > 0.2 2.71 1.34; 5.51 0.006 1.25 0.46; 3.44 0.659 2.45 0.81; 7.38 0.112 2.57 1.38; 4.76 0.003
Angiolymph. invasion
- No 1 1 1
- Yes 1.98 0.96; 4.09 0.066 1.7 0.58; 5.01 0.329 0.95 0.33; 2.75 0.927
Neural invasion
- No 1 1 1
- Yes 1.14 0.55; 2.38 0.729 1.3 0.43; 3.91 0.64 0.77 0.22; 2.67 0.684
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an independent prognostic factor in our study. Depth in-
vasion has also been described in several other studies as
a prognostic factor independent of nodal status [16,17].
Similarly, the importance of tumor length or its develop-
ment location have been described [18].
Preoperative tumor stenosis was found in our study to
be an independent risk factor of local relapse that, toour knowledge, has never been previously reported. This
is the main new factor identified in our study. The inter-
est of this factor, simply defined on endoscopic and/or
barium swallow criteria, is its preoperative availability.
Despite its clear clinical correlation with a high pT stage,
quality of resection but also with nutritional status, it
appears, statistically, to be an independent risk for local
relapse and not for distant relapse. It could represent an
Figure 2 Kaplan-Meier Relapse Free Survival curves according to the number of risk factors (p < 0.001).
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tive chemoradiotherapy or in the indication of trans-
thoracic vs transhiatal approach to get an optimal local
disease control. Indeed, there is evidence that preopera-
tive chemoradiotherapy increases the rate of complete
resection i.e. local control for patients with locally ad-
vanced disease even if this was not always translated into
a survival benefit in individual studies [19,20]. Similarly,
transthoracic approach allows greater lymphadenectomy
(eight more lymph node retrieved compared with trans-
hiatal approach) [21] that might provide increased local
control and disease free survival [22].
Several other risk factors of recurrence, very different,
have been described as circumferential margin involve-
ment [23,24], involvement of subcarinal and lower para-
oesophageal lymph nodes [25], tumor-stroma ratio [26],
endoscopic tumor length [27], good performance status
of the patient [28]. Even if tumor stage and lymph node
ratio are probably the most relevant risk factors of recur-
rence, this kind of studies, as ours, are necessary to re-
fine oesophagus cancer prognosis and to help in the
decision for adjuvant therapy.
Locoregional recurrence has been described with lon-
ger survival than distant or disseminated recurrence par-
ticularly in case of cervical recurrence [29,30]. On the
other hand, Bhansali et al. [31] reported no difference in
different types of recurrence. In our report, survival in
case of local recurrence was surprisingly 3 months
shorter than for distant recurrence. This is probably due
to differences in treatment protocol after relapse.
Half of our patients presented with pT < 3 or negative
preoperative lymph node status. That partly explains our
low rate of patient who received preoperative treatment
(30%). Moreover, the length of our study, begun in 1998,is another explanation, first main studies of neo-adjuvant
treatment still not published at that time. Finally, low rate
of 50% of preoperative EUS performed may have led to a
preoperative downstaging and also explains the rate of
preoperative treatment.
A same approach was performed with overall survival
and brought similar results. As our study focused on re-
currence risk, these results are not detailed here. Five
year overall survival estimated by Kaplan Meier method
was 49% in our survey. This result, higher than OS re-
ported in literature [1], may be due to our high rate of
low stage tumors and drastic patient selection for surgi-
cal treatment.
Adenocarcinoma and squamous cell carcinoma were
both included in this study that may be a bias. Indeed,
Siewert et al. [32] reported two different diseases with
different pathogenesis, epidemiology, tumor biology and
prognosis requiring different therapeutic strategies.
However, focusing on relapse and survival, several stud-
ies comparing adenocarcinoma and squamous cell car-
cinoma have reported worse, similar or better survival
according to histopathology [33-35]. In our study, histo-
pathology doesn’t appear to be correlated to RFS and OS
and multivariate analysis allowed us to statistically study
all of our patients in the same cohort. Signet ring cell
adenocarcinoma is well known to have poorer prognosis
[36]. Our number of patient and particularly with signet
ring cell was too small to study it as a risk factor.
This study might initiate thinking for patients who re-
ceived neoadjuvant treatment as indicated in guidelines,
if they could benefit, in presence of these risks factors,
of post-operative treatment or of a more intensive cli-
nical or radiological follow-up. Moreover, recurrence
risk is directly correlated with the number of positive
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creating a risk score of recurrence, what may ponder dis-
cussion according to this score. Our score has to be con-
firmed by others studies but strongly argue for adjuvant
therapy in case of cumulated risks, particularly in case of
tumor regression after preoperative treatment.
Limitations of this study are numerous. The main is it
retrospective type, while conducted on a homogeneous
group of patients, that has led to heterogeneity in pre-
operative administrated treatments. These results have to
be confirmed in a prospective one with standardized pro-
tocols. Then, monocentric aspect of the study allowed us
to analyze patients with standardized practices but repre-
sents also a bias as the results must be confirmed in multi-
centric studies. Besides, our department is not a high
volume center for oesophageal surgery, due to a low inci-
dence of oesophageal cancer in our county, but belongs to
the university hospital and is experienced in oesophago-
gastric surgery.
Conclusion
Finally, our study demonstrates that preoperative tumor
stenosis is the only prognostic factor associated with an
increased risk of local relapse. Concerning relapse free
survival, pT stage > 2, positive lymph node status and
lymph node ratio > 0.2 are independent prognostic factors
of recurrence after Ivor-Lewis surgery for cancer. Further-
more, addition of these risk factors is correlated with an
increasing risk of recurrence. Thus, a routine postopera-
tive treatment or reinforced follow-up should probably be
considered in patients combining these risk factors.
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